ALQGC Fundamental Analysis - QUANTUM GENOMICS SAS-REGR

Fundamental Rating

Taking everything into account, ALQGC scores 1 out of 10 in our fundamental rating. ALQGC was compared to 83 industry peers in the Biotechnology industry. Both the profitability and financial health of ALQGC have multiple concerns. ALQGC has a valuation in line with the averages, but on the other hand it scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALQGC has reported negative net income.

ALQGC had negative earnings in each of the past 5 years.

ALQGC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ALQGC (-84.63%) is worse than 80.00% of its industry peers.

The Return On Equity of ALQGC (-726.18%) is worse than 75.71% of its industry peers.

		Industry Rank	Sector Rank
ROA	-84.63%
ROE	-726.18%
ROIC	N/A

ROA(3y)-87.78%

ROA(5y)-71.29%

ROE(3y)-517.57%

ROE(5y)-335.54%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALQGC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALQGC does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALQGC remains at a similar level compared to 1 year ago.

The number of shares outstanding for ALQGC has been increased compared to 5 years ago.

Compared to 1 year ago, ALQGC has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -11.61, we must say that ALQGC is in the distress zone and has some risk of bankruptcy.

ALQGC has a worse Altman-Z score (-11.61) than 84.29% of its industry peers.

A Debt/Equity ratio of 4.49 is on the high side and indicates that ALQGC has dependencies on debt financing.

Looking at the Debt to Equity ratio, with a value of 4.49, ALQGC is doing worse than 72.86% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	4.49
Debt/FCF	N/A
Altman-Z	-11.61

ROIC/WACCN/A

WACC7.48%

2.3 Liquidity

A Current Ratio of 2.73 indicates that ALQGC has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 2.73, ALQGC is in line with its industry, outperforming 60.00% of the companies in the same industry.

A Quick Ratio of 2.73 indicates that ALQGC has no problem at all paying its short term obligations.

ALQGC has a Quick ratio (2.73) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.73
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.28% over the past year.

ALQGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.34%.

The Revenue for ALQGC have been decreasing by -79.70% on average. This is quite bad

EPS 1Y (TTM)87.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.58%

Revenue 1Y (TTM)-98.34%

Revenue growth 3Y-79.7%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y6121.43%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year1744.53%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALQGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 0.02, the valuation of ALQGC can be described as very cheap.

Compared to the rest of the industry, the Price/Forward Earnings ratio of ALQGC indicates a rather cheap valuation: ALQGC is cheaper than 100.00% of the companies listed in the same industry.

ALQGC is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.83, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.02

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALQGC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALQGC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

QUANTUM GENOMICS SAS-REGR

EPA:ALQGC (10/24/2024, 7:00:00 PM)

0.0721

0 (-1.77%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-22 2024-10-22

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap5.00M

Revenue(TTM)10.06K

Net Income(TTM)-3.17M

Analysts34.29

Price Target10.2 (14047.02%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.02
P/S	496.96
P/FCF	N/A
P/OCF	N/A
P/B	11.45
P/tB	11.45
EV/EBITDA	N/A

EPS(TTM)-0.09

EYN/A

EPS(NY)4.34

Fwd EY6021.43%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS0.01

TBVpS0.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-84.63%
ROE	-726.18%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-87.78%

ROA(5y)-71.29%

ROE(3y)-517.57%

ROE(5y)-335.54%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	4.49
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.73
Quick Ratio	2.73
Altman-Z	-11.61

F-ScoreN/A

WACC7.48%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)87.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.58%

EPS Next Y6121.43%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-98.34%

Revenue growth 3Y-79.7%

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year1744.53%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y89.57%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year3919.47%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ

What is the fundamental rating for ALQGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALQGC.PA.

What is the valuation status for ALQGC stock?

ChartMill assigns a valuation rating of 4 / 10 to QUANTUM GENOMICS SAS-REGR (ALQGC.PA). This can be considered as Fairly Valued.

How profitable is QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) has a profitability rating of 0 / 10.

What is the financial health of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

The financial health rating of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) is 3 / 10.

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ

What is the fundamental rating for ALQGC stock?

What is the valuation status for ALQGC stock?

How profitable is QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

What is the financial health of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?